Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics
CRNX Price/Volume Stats
| Current price | $53.80 | 52-week high | $55.78 |
| Prev. close | $51.23 | 52-week low | $25.35 |
| Day low | $51.59 | Volume | 515,200 |
| Day high | $53.85 | Avg. volume | 785,963 |
| 50-day MA | $51.90 | Dividend yield | N/A |
| 200-day MA | $44.06 | Market Cap | 4.24B |
CRNX Stock Price Chart Interactive Chart >
Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.
Latest CRNX News From Around the Web
Below are the latest news stories about CRINETICS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRNX as an investment opportunity.
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...On December 21, 2023, Chief Med and Dev Officer Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), as indicated by an SEC Filing. |
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid SyndromeSignificant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Results Expected in 1H 2024 Management to Host a Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial f |
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on December 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-execu |
12 Stocks Billionaire Steve Cohen Just Bought and SoldIn this article, we’re going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought and Sold. Billionaire Steve Cohen is one of the most […] |
Crinetics Pharmaceuticals to Participate in Upcoming Investor ConferencesSAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6th Annual Evercore ISI HealthCONx Conference:Date: Tuesday, November 28, 2023Time: 3:50 p.m. Eastern Time Piper Sandler 35th Annual Healthcar |
CRNX Price Returns
| 1-mo | 4.22% |
| 3-mo | 20.33% |
| 6-mo | 19.08% |
| 1-year | 82.43% |
| 3-year | 128.55% |
| 5-year | 204.30% |
| YTD | 51.21% |
| 2023 | 94.43% |
| 2022 | -35.59% |
| 2021 | 101.35% |
| 2020 | -43.76% |
| 2019 | -16.34% |
Continue Researching CRNX
Want to do more research on Crinetics Pharmaceuticals Inc's stock and its price? Try the links below:Crinetics Pharmaceuticals Inc (CRNX) Stock Price | Nasdaq
Crinetics Pharmaceuticals Inc (CRNX) Stock Quote, History and News - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...